Helix BioPharma Corp. (HBP.TO) TSX
1.58
+0.02(+1.28%)
Currency In CAD
- General
- Statistics
- Historical Data
- Profile
- Financials
Helix BioPharma Corp.
Address
9120 Leslie Street
Richmond Hill, ON L4B 3J9
Canada
Phone
905 841 2300
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
August 13, 1996
Key Executives
| Name | Title | Pay | Year Born |
| Thomas Mehrling | CEO & Chief Medical Officer | 318,920 | N/A |
| Jacek Antas | Chairman & Corporate Secretary | 100,000 | N/A |
| Davide Guggi | Chief Technology Officer | 213,599 | N/A |
| Veronika Kandziora | Chief Operating Officer | 232,241 | N/A |
| Rohit Babbar | Chief Financial Officer | 243,768 | N/A |
| Natalia L. Butterworth | Corporate Secretary | 0 | N/A |
| Helen Middleton | General Counsel | 0 | N/A |
| Jessica Kourniaktis DPHIL | Director of Communications | 0 | N/A |
Description
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
